89371-34-6

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 82717-96-2 [1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanine 
• 82717-95-1 Benzyl (2S)-2-amino>propionate 
• 97457-39-1 Benzyl (2S)-2-amino>propionate Hydrogenmaleate 
• 90891-21-7 L-(+)-α-amino-4-phenylbutyric acid ethyl ester hydrochloride 
• 85196-26-5 (2R)-2-amino>propionic acid 
• 111542-00-8 (S)-2-((R)-1-Benzyloxycarbonyl-ethylamino)-4-phenyl-butyric acid ethyl ester; hydrochloride 
• 93841-86-2 benzyl (2R)-2-amino>propionate 
• 943-73-7 D-homophenylalanine 
• 5440-40-4 2-(acetylamino)-4-phenylbutanoic acid 
• 1012-05-1 D,L-homophenylalanine 
• 16503-46-1 2-bromo-4-phenyl butanoic acid 
• 82586-61-6 ethyl 2-bromo-4-phenylbutanoate 

Downstream Products

• 83647-97-6 spirapril 
• 117605-19-3 (4S)-3-<(2R)-2-amino>propionyl>-1-methyl-2-oxoimidazolidine-4-carboxylic acid 
• 94841-17-5 spirapril hydrochloride 
• 117605-23-9 tert-Butyl (4S)-3-<(2S)-2-amino>propionyl>-1-methyl-2-oxoimidazolidine-4-carboxylate Hydrogenmaleate 
• 89396-94-1 Imidapril hydrochloride 
• 83602-05-5 Spiraprilat 
• 75847-73-3 enalapril 

Relevant academic research and scientific papers

One-pot formation of succinimidyl esters by the system chlorophosphate/hydroxysuccinimide/base

Succinimidyl esters of various carboxylic acids are formed in high yield at ambient to slightly elevated temperature by the system chlorophosphate/hydroxysuccinimide/base.

Studies on Angiotensin Converting Enzyme Inhibitors. 4. Synthesis and Angiotensin Converting Enzyme Inhibitory Activities of 3-Acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic Acid Derivatives

(4S)-1-Alkyl-3-acyl>-2-oxoimidazolidine-4-carboxylic acid derivatives (3) were prepared by two methods.Their angiotensin converting enzyme (ACE) inhibitory activities and antihypertensive effects were evaluated, and the structure-activity relationships were discussed.The dicarboxylic acids 3a-n possessing S,S,S configuration showed potent in vitro ACE inhibitory activities with IC 50 values of 1.1x10-8-1.5x10-9 M.The most potent compound in this series, monoester 3p, had an ID 50 value of 0.24 mg/kg, po for inhibition of angiotensin I induced pressor response in normotensive rats and produced a dose-dependent decrease in systolic blood pressure of spontaneously hypertensive rats (SHRs) at doses of 1-10 mg/kg, po.

Angiotensin Converting Enzyme Inhibitors: Spirapril and Related Compounds

The synthesis of spirapril (5), spiraprilat (25), their RSS stereoisomers, and their glycyl (18b) and lysyl (36, 37) analogues is described.These compounds were evaluated in vivo for inhibition of angiotensin converting enzyme (ACE), and selected compounds were evaluated for in vitro ACE inhibition (spirapril ID50 16 μg/kg; spiraprilat IC50 0.8 nM, ID50 8 μg/kg).In anesthetized rats, iv, esters 5 and 36 are more potent than enalapril, and diacids 25 and 37 are more potent than enalaprilat in vitro.In the conscious rats, orally, 5 and enalapril (2) showed potent and sustained activity at doses of 0.03-1 and 0.1-1 mg/kg, respectively.From this work, spirapril was selected for clinical evaluation as an antihypertensive agent.